
A systematic review and meta-analysis were conducted to assess whether coronary revascularization improves outcomes in heart failure (HF) patients receiving guideline-recommended pharmacological therapy (GRPT). Five randomized controlled trials (RCTs) involving 2,842 patients were included. The results showed that compared to medical therapy alone, coronary revascularization was associated with a lower risk of all-cause mortality and cardiovascular mortality. However, there was no significant difference in the composite outcome of hospitalization for HF or all-cause mortality. The study suggests that further trials are needed to determine which HF patients with coronary artery disease (CAD) would benefit most from coronary revascularization.
Like
Save
Share